Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported strong FY25 results with revenue of ₹2,687 Mn, up 28.8% YoY, and operating EBITDA of ₹579 Mn, up 59.1%, with margins expanding 410 bps to 21.5%. Q4FY25 revenue grew 34.7% to ₹586 Mn with EBITDA up 96.6% to ₹97 Mn. Business PAT for the year rose 66.7% to ₹375 Mn. The company is debt-free with a cash balance of ₹1,456 Mn and has recommended a 125% dividend (₹2.5 per share). Key milestones include the Yash Pharma acquisition (May 2024, ₹924.7 Mn), the divestment of the Faridabad facility for ₹410 Mn, and Indocap becoming the company's first ₹50 Cr brand. A proposed acquisition of Resilient Cosme-Ceuticals was called off due to unmet conditions.
Strong results with robust revenue growth, expanding margins, and a healthy dividend signal positive operational momentum. Clear forward guidance of 15%+ revenue growth and 100-150 bps margin expansion for FY26, along with continued inorganic ambitions, could support investor sentiment and stock price.